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1. Introduction
1.1. Phytochemicals in the cucurbitaceae
The seeds of several species are a rich source of proteins, lipids, unsaturated fatty acids (table
1), phytosterols, vitamin E, and some minerals such as Mn, Zn, Cu, and carotenoids. The flesh
of the fruits also contains some important compounds, such as flavonoids, that show antioxi‐
dant activity.
Other phytochemicals in the cucurbits are scarce, but polysaccharides is important to mention.
These compounds, bound to proteins, are often considered as key active compounds in some
species particularly with regards to diabetes. Alkaloids and saponins have been described in
Momordica and Sechium, and also polyamines and galactolipids. In Sechium, the presence of
proteins with ribosome-inhibiting activities has been described.
Crop Water (%) Calories
(kcal)
Protein (g) Fat (g) Carbohydrate (g) Fiber (g)
Melon
cantaloupe 90 35 0.9 0.3 8.4 0.8
Caaba 92 26 0.9 0.1 6.2 0.8
Honeydew 90 35 0.5 0.1 9.2 0.6
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Crop Water (%) Calories
(kcal)
Protein (g) Fat (g) Carbohydrate (g) Fiber (g)
Winter squash
Acorn 80 40 0.8 0.1 10.4 1.5
Butternut 86 45 1.0 0.1 11.7
Hubbard 88 40 2.0 0.5 8.7
Spaghetti 92 31 0.6 0.6 6.9
Summer squash 94 20 1.2 0.2 404 1.9
Cucumber 96 13 0.7 0.1 2.8 0.8
Watermelon 92 32 0.6 0.4 7.2 0.5
Bitter gourd (momordica) 94 17 1.0 0.2 3.7 2.8
Wax gourd (Benincasa) 96 13 0.4 0.2 3.0 2.9
Luffa gourd (Luffa) 94 20 1.2 0.2 4.4
Calabash gourd (Lagenaria) 96 14 0.6 0.02 3.4
Chayote (Sechium) 94 19 0.8 0.1 4.5 1.7
Pumpkin and squash, seeds 7 541 24.5 45.9 17.8 3.9
Watermelon, seeds 5 557 28.3 47.4 15.3
Data obtained from the US Department of Agriculture, Agricultural Research Service (2001) USDA Nutrient Database
for Standard Reference, Release 14. Nutrient Data Laboratory Home (www.nat.usda.gov/fnic/foodcomp).
Table 1. Nutrient composition of Cucurbits in 100-g edible raw portion
2. Cucurbitacins
The cucurbitacins, as characteristic compounds of many species of the cucurbits, are tetracyclic
triterpenes arising from a rearrangement of the protostane cation. They are unsaturated and
polyfunctional oxygenated compounds and occur most often as glycosides. They are particu‐
larly toxic substances, the bitterness and cytotoxicity being the contributing factors for this
toxicity [1].
They are divided into twelve groups, from cucurbitacin A to cucurbitacin T. The cucurbita‐
cin I, B, D, E, and L the most used in vivo  and in vitro  studies and differ by the acetyla‐
tion of groups OH or by the presence of double bond (Figure 1) that increase the lipophilic
and toxic properties [2, 3].
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Figure 1. The chemical structure of major cucurbitacins
3. Physical properties and solubility of cucurbitacins
Some of the cucurbitacins are crystalline solids, but others are gums or semisolids and their
structure contribute to their scarce solubility in water and this factor is a challenge in pursuing
their biological activity. There are some studies [4, 5, 6] that tried to search how to deliver the
active principle without this problem, such as the use of polymeric micelles for nanoscale drug
delivery. The amphiphilic block copolymers has the capacity to accommodate several types of
molecules for drug delivery and the poly(ethylene oxide)-block-poly(ε-caprolactone) called
PEO-b-PCL, which is a biocompatible copolymer successfully used for the solubilization of
compounds of poor solubility in water, is suitable for solubilization and controlled delivery
of cucurbitacin I and B [6].
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4. Bioactivity of cucurbitacins
Besides their cytotoxic and anticancer activity, they also show other pharmacological effects
in vivo as in in vitro, for example, as purgative, anti-inflammatory, cough, flu, fever, or anti-
fertility. They also show other functions as plant growth regulators and antifeeding agents in
insects. A combination of cucurbitacins B + E glucosides showed a notorious antioxidant
activity and it is believed that their beneficial properties are due to their ability to interact with
reactive oxygen species [10]. It is know that nitric oxide has various functions, but its uncon‐
trolled production can be toxic in many pathological conditions, such as the inflammatory
tissue damaged, and in this connection some members of the Cucurbitaceae family have been
tested as potential inhibitory agents for nitric oxide production [11]. From Hemsleya pengxia‐
nensis, Dihydrocurbitacin F-25-O-acetate was isolated as one of the main components and it
was shown that this compound plays a main role as an anti-infection agent [12].
It was shown that at the molecular level, the cucurbitacins have a role in the inhibition of the
JAK/STAT3 pathway that is a major contributor in oncogenesis and five cucurbitacins were
tested, A, B, E, I, and Q, and found that the last one inhibit the activation of STAT3 but not
JAK2, instead cucurbitacin A inhibit JAK2 but not STAT3 and the cucurbitacins B,E, and I
inhibit the activation of both. Furthermore, cucurbitacin Q but not A induces apoptosis and
inhibits human tumor growth in mice [13]. To validate these interesting results, another model
was described in the Sézay syndrome(Sz), which is an aggressive lymphoma/leukemia of the
skin, that used cucurbitacin I to inhibit the JAK/STA3 pathway [16] and it was demonstrated
that inhibition of STAT3 using cucurbitacin I induced apoptosis of the cells and it was
mentioned that this inhibitor of STAT3 is a potent therapeutic agent for Sz.
Cucurbitacin B and R isolated from Cayaponia tayuya induced dramatic changes in the cytos‐
keleton, inhibiting proliferation and induced apoptosis of isogenic colon cancer cell lines
HCT116 and Hke-3 [14]. The cucurbitacin glucosides extracted from Citrillus colocynthis leaves
effects on human breast cancer cell growth and it is suggested that this kind of glucosides
exhibit pleitropic effects on cells causing both cell cycle arrest and apoptosis [13].
Also, the cucurbitacin E has demonstrated some interesting results because it has emerged in
one empirical screening strategy to define agents with potent growth inhibitory activity. It was
demonstrated that one early effect of this cucurbitacin is the rearrangement of the actin and
the vimentin cytoskeleton. The growth inhibitory actions of a series of cucurbitacins correlate
with these effects and that the actin and vermectin cytoskeleton are potential targets for this
kind of compounds [17].
In another model with cucurbitacin B isolated from Trichosanthes cucurmerina, it was demon‐
strated that this compound has a cytotoxic effect on breast cancer cell lines SKBR-3 and MCF-7
and that growth inhibition was attributed to G2/M phase arrest and apoptosis and also that
the cucurbitacin B mediates its effect by inhibiting the translocation of β-catenin and galectin-3
proteins to the nucleus rather than by disrupting the β-catenin/galectin-3/TCF-4 complex
formation. This means that cucurbitacin B targeting of the Wnt signaling pathway could be an
innovative approach for breast cancer treatment [19].
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It was observed that when an antitumor agent, such as doxorubicin (DOX), is combined with
some natural products such as capsaicin derivatives, gingerol, ferulic acid, or cucurbitacin E,
it has a notorious effect on tumor cells. The first ones did not change DOX permeability in the
tumor cells but instead cucurbitacin E significantly promoted DOX influx into the tumour cells
and maintained its levels in the tumour cells [18].
In another model, the induction of cancer cell-specific apoptosis via activation of TRAIL
(tumour necrosis factor-related apoptosis-inducing ligand) signaling has become an important
focus of cancer research and in this sense it was found that cucurbitacins B and D were among
the sensitizers of cancer cells to TRAIL-mediated apoptosis in a high-throughput screen [32].
It was found that sensitization by these cucurbitacins is rapid and persistent, making them
potentially useful reagents for developing increased understanding of the sequence of
molecular events that can lead to TRAIL sensitization and subsequent apoptosis.
The model of proteasome is another approach to understand the molecular mechanism of
chemotherapeutic agents. It was found that the proteasome is an abundant catalytic complex
present in both nucleus and cytoplasm of eukaryotic cells. Proteasome-mediated degradation
plays an essential role in the regulation of most intracellular proteins such as NF-κB and
recently proteasome inhibitors have been used as a new anticancer therapy. In this sense it
was found that cucurbitacin D induced apoptosis through suppression of proteasome activity
both in vivo and in vitro, making this compound a promising candidate for clinical applications
in the treatment of T-cell leukemia [20].
5. Response of cancer cells to cucurbitacin exposure
Like other plant-derived substances, cucurbitacins induce toxicity in different cancer cell lines
with several morphological and physiological changes (Table 2). Drastic changes in cell shape,
such as rounding, swelling, pinocytic blebbing, submembranous inclusions, and blisters, are
observed within a couple of hours. Some of the morphological changes could be explained by
the dysregulation of cytoskeleton homeostasis by cucurbitacins. Duncan et al. reported a
dramatic increase in F-actin to G-actin ratio and abnormal reorganization of the vimentin
network by cucurbitacin E in human prostate cancer cell lines [17, 28]. Studies with cucurbi‐
tacin B also showed the aggregation of F-actin in various human cancer cell lines [29, 30, 31],
implying the disruption of the dissociation process of F-actin by an unknown mechanism.
However, unlike vinca alkaloids and taxanes, there is no clear evidence that cucurbitacin
affects the microtubule network.
Multinucleation is another common morphological change that was consistently reported in
human cancer cell cultures exposed to cucurbitacin for more than 24 h. According to Duncan
et al., multinucleation implies that cucurbitacin blocks cytokinesis, but not karyokinesis [17].
This is in conjunction with the observation that actin (which is involved in cytokinesis) is
disrupted, whereas microtubules (which are involved in karyonesis) are not.
Multinucleation can result from the disruption of the cell cycle. Many reports showed that
cucurbitacins induced cell cycle arrest, mostly in the G2/M phase [31, 32, 33, 39], but S-phase
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arrest in HL-60 and U937 human leukaemia cell lines was also reported [11]. G2/M arrest
happens in the early period of cucurbitacin exposure and results in apoptotic death of the
tumor cells [39]. Tannin-Spitz et al. showed that G2/M arrest occurred in breast cancer cell lines
(MCF-7 and MDA-MB-231) exposed to cucurbitacin B/E glucosides by the inhibition of cyclin-
dependent kinase (cdk) p34 CDC2 and cyclin B1, both in expression level and activation status
[33]. G2/M has shown arrest by upregulation of cdk inhibitor p21WAFI, and by downregulation
of cyclin A and cyclin E in pancreatic cancer cell lines (Panc-1 and MiaPaCa-2) exposed to
cucurbitacin B [32].
6. Cucurbitacins and their molecular mechanism of action
By what molecular mechanism do cucurbitacins achieve cell cycle arrest, apoptosis, and
growth suppression of cancer cells? There are several oncogenic signaling pathways that are
commonly involved in cancer cell proliferation and survival. The JAK-STAT pathway, the Akt-
PKB pathway, and the MAPK pathway are important in cancer cells and are also targets of the
cucurbitacin family.
The JAK-STAT pathway induces Janus-kinases (JACKs) and signal transducers and activators
of transcription (STATs), and regulates cytokine and growth factor signals (Figure 2). In many
cancer cells, constitutive activation of STAT3 and STAT5 has been known to play important
roles in tumorigenesis [34]. After the initial finding by Blaskovich et al. that cucurbitacin I
(JSI-124) is a dual inhibitor of STAT3 and JACK [16], many studies confirmed that cucurbitacin
I is a powerful JAK-STAT inhibitor by blocking the tyrosine phosphorylation of STAT3 and
JAK2 in various human cancers [33, 35, 36, 37, 38, 39]. However, cucurbitacin I did not affect
other oncogenic signaling pathways, such as the Akt-PKB or MAPK/ERK pathways [35].
Furthermore, it has been discovered that cucurbitacin B inhibits the tyrosine phosphorylation
of STAT3, STAT5, and JAK2 in pancreatic cancer cell lines (Panc-1 and MiaPaCa-2) in vitro and
in Panc-1 xenografts in vivo [32]. Inhibition of the JACK-STAT pathway affected various
downstream targets involved in progrowth signaling (e.g., c-myc, cyclins, surviving) and
apoptosis (e.g., p53, Bcl-xL, Bcl-2) [34, 36]. Therefore G2/M arrest and apoptosis in pancreatic
cancer cells exposed to cucurbitacin B could be explained as a result of inhibition of the JAK-
STAT pathway and was confirmed by the downregulation of p21WAFI, cyclin A, and cyclin E,
and upregulation of Bcl-xL. Like cucurbitacin I, cucurbitacin B did not inhibit other progrowth
signaling pathways, such as the Akt/PKB and MAPK/ERK pathways in pancreatic cancer cells
[32]. Interestingly, Sun et al. found that cucurbitacin A, which only differs with cucurbitacin
B by its C-11 hydroxyl group, lost its activity as a STAT3 inhibitor while maintaining its activity
as a JACK2 inhibitor [36], showing that the inhibition of STAT3 and JAK2 may follow different
molecular mechanisms.
The anti-cancer mechanism of cucurbitacin in breast cancer cells is still not clear. Tannin-Spitz
et al. exposed breast cancer cell lines (MCF-7 and MDA-MB-231) to cucurbitacin B/E glucosides
and found that cucurbitacins increased the tyrosine phosphorylation of STAT3, unlike other
cancers [33]. Considering the activated JAK-STAT pathway in breast cancer [34], this result
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was contradictory. The authors hypothesized that concurrent inactivation of PBK in a cell type-
specific manner might explain this unique regulation, which requires further research.
Considering the important role of STAT3 during inflammation [40], it is not surprising that
part of the anti-cancer activity of cucurbitacins is linked to their anti-inflammatory activity.
Chronic inflammation can make individuals predisposed to many types of cancer [40]. This
seems to affect both cancer cells and normal macrophages through different mechanisms. In
cancer cells, cucurbitacins work as STAT3 inhibitors, and make cells more susceptible to the
attack of reactive oxygen species (ROS) and free radicals during inflammation [43]. In normal
macrophages, however, cucurbitacins work as inhibitors of the IKK/NF-κB pathway rather
than inhibitors of STAT3 [42, 43]. Inhibition of the IKK/NF-kB pathway by cucurbitacins results
in the inhibition of key inflammatory enzymes, such as cyclooxygenase-2 (COX-2) and
inducible nitric oxide synthase (iNOS), whose overproduction contributes to tumorigenesis
[41, 42, 43]. However, it is still not clear how cucurbitacins can selectively choose their target
pathway depending on cell type.
Interestingly, when Escandell et al. used two human colon cancer cell lines without activated
STAT3 (HCT116 and Hke-3), 23,24-dihydrocucurbitacin B and cucurbitacin R still suppressed
tumour growth at a significant level [44]. Furthermore, the presence of active kRas in HCT116
cells showed more protection from apoptosis than Hke-3 cells, which do not have active kRas
[25]. Since kRas is upstream of ERK, the result implies the effect of cucurbitacins on the MAPK
pathway.
Indeed, the MAPK signaling cascade was another target that cucurbitacins acted upon. It has
been shown that cucurbitacin B affects the MAPK pathway in glioblastoma (GBM) multiforme
cells in vitro [31]. Cucurbitacin B-treated GBM cells showed an increased level of phosphory‐
lated p38, phosphorylated JNK,and phosphorylated c-Jun, as well as a decreased level of
phosphorylated ERK at the same time. Upregulation of JNK may induce apoptosis in GBM
cells, and downregulation of p38 and ERK may block cytokine signaling. Chan et al. also
showed that both phosphotyrosine-STAT3 and phospho-ERK were suppressed in the K562
leukemia cell line [45]. Increased JNK phosphorylation by cucurbitacin D in the Hep3B human
hepatocellular carcinoma cell line was also reported [46].
The Akt-PKB pathway mediates signals from receptor tyrosine kinases (RTHKs) and integrins.
Currently, no cucurbitacins are known to inhibit the phosphorylation of Akt. Although
Tannin-Spintz et al. showed the downregulation of PKB in breast cancer cell lines [33], further
research is required to confirm the effect of cucurbitacin on the Akt-PKB pathway.
7. Synergistic effect of cucurbitacins with chemotherapeutic agents
Despite its excellent anti-cancer activity, clinical use of cucurbitacin has challenges to over‐
come, such as low therapeutic index and nonspecific toxicity. One of the solutions to these
problems would be the use of cucurbitacins in combination, not only to enhance the efficacy
of the treatment, but also to avoid the build-up of resistance in cancer cells. Moreover, some
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drug combinations show strong synergism that helps to achieve the same therapeutic effect
with a lower dose, and hence less toxicity. Encouragingly, some reports have shown that
cucurbitacins show a synergistic effect with chemotherapeutic agents that are already estab‐
lished in the treatment of human cancers.
Saduka et al. showed that cucurbitacin E promotes cellular accumulation of doxorubicin, both
by facilitating influx to and by preventing efflux from the tumour cells, implying synergistic
effects of the two drugs [47]. Another study by Ramalhete et al. using cucurbitacin derivatives
from Momordica balsamica confirmed statically the synergistic effect of some cucurbitacin
derivatives and doxorubicin using the fractional inhibitory concentration index (FIX) [48].
Recently, the synergistic effect of cucurbitacin B with gemcitabine in pancreatic cancer was
discovered [32]. Using an isobologram and combination index (CI) method, it was shown that
in a certain concentration range, cucurbitacin B and gemcitabine showed a CI value less than
0.9, which showed synergism between two drugs in vitro.
Strikingly, cucurbitacin B induced no apparent toxicity in vivo [32]. As a single agent at high
dose (1.0 mg/kg), cucurbitacin B induced a slight body weight loss after the first treatment, but
no further toxicity was observed during the seven weeks of treatment. Any signs of toxicity
after treatment were searched for using various immunohistochemistry stainings on major
organs such as the liver, spleen, and kidney, as well as a blood and serum chemistry test.
However, no signs of toxicity by cucurbitacin B were found. Considering the high dose of
cucurbitacin B near LD50 value (1.1 mg/kg) [26], the result was remarkable.
As Raikhlin-Eisenkraft et al. pointed out, many factors can affect the toxicity of cucurbitacins
[25]. The bioreactivity of a compound can vary greatly depending on the presence of other
compounds and the microenvironment in vivo. The discrepancy between the results and
previous case reports can be partly explained by the extent of purity of cucurbitacins. Rapid
advances in purification technology over the decades may have eliminated the other impurities
coeluted with cucurbitacins from the plant source, which may be the true cause of toxicity in
the past. Changes in the type of solvents for elution and dilution can also play a role. Defective
immune system in athymic nude mice can be another possibility. For this reason, it was
suggested that cucurbitacin toxicity in humans needs to be re-studied and should not be the
reason to rule it out as a potential anti-cancer drug.
Cucurbitacin Plant Source Effectiveness on cancer cell lines
Cucurbitacin A Trichosanthes cucumerina (snake
gourd)
Lung: A549 cell lines
Cucurbitacin B Trichosanthes cucumerina
(snakegourd)
Cucurbita andreana (buttercup
squash).
Wibrandia ebracteata.
Leukemia and lymphoma: HL60, U937, THP1, NB4,
K562, BALL1, Reh, RCH, LY4, Daudi, D901, SP49,
Jeko1 and NCEB1. Hepatocellular: Hep-2. Breast:
SKBR2, MCF-7, T47D and MDA-B435. Lung: A549, SK
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Cucurbitacin Plant Source Effectiveness on cancer cell lines
(no common name)
Luffa operculata
(Sponge Cucumber)
LU1 and NCI-H460. Colon: COCA-2 and HCT-116.
Brain: SF-268. Pancreatic cancer cell lines.
Cucurbitan glucosides Citrullus colocynthis
(Bitter cucumber)
Breast: ER+MCF-7 and ER´MDA- MB231.
Cucurbitacin E
& its glucoside (Elaterin)
Bacopa monnieri
(Water hyssop)
Cucurbita andreana
(winter Squash)
Citrullus colocynthis.
(Bitter cucumber)
Ovarian sarcoma: M5076. Colon: HCT-116
Breast: MCF-7 and ZR-75-1. Lung: NCI-H460.
Brain: SF-268. Prostate: PC-3 Hepatocellular: HepG2
Cucurbitacin D
(Elatericin A)
Trichosanthes kirilowii
(Chinese Cucumber)
Cucurbita andreana
(Winter Squash)
Hepatocellular: Hep-2. Leukemia and lymphoma:
HL60, U937, THP, BALL1, Reh, RCH, LY4, Daudi,
MD901, SP49, Jeko 1 and NCEB1. Breast: MCF-7
Colon: HCT-116. Lung: NCI-H460. Brain: SF-268
Dihydrocucurbitacin B Wibrandia ebracteata
(no common name)
Trichosantes kirilowii
(Chinese Cucumber)
Cayaponia tayuya
(Tayuya)
Leukemia. Hepatocellular Hep-2. Breast: Bcap37 Hela,
SW620, SMMC-7721, K562 and MCF-7. Colon: HCT116
and Hke3.
Cucurbitacin I
& its glucoside
(Elatericin B)
(JSI 124)
Momordica balsamina L
(Balsam pear).
Cayaponia tayuya.
(Tayuya)
Cucurbita andreana.
(Winter Squash)
Citrulus colocynthis
(Bitter cucumber)
Colon HCT-116. Breast: MCF-7, MDA-MB-231, MDA-
MB-468, and Panc-1. Lung: NCI-H460. Brain: SF-268.
Gliboblastomamultiforme: Y251 and A172.
Hepatocellular: Hep-G2
Cucurbitacin Q Cayaponia tayuya.
(Tayuya)
Lung: A549 Human and murine cancers: A549, Mda-
MB-435 and v-SRV/NIH 3T3
Cucurbitacin R Cayaponia tayuya
(Tayuya)
Colon: HCT 116 and Hke-3
Table 2. Cucurbitacin compounds from different plant species and their bioactivity on cancer cells.
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Figure 2. Mechanism of activation of Janus kinases and signal transducer and activator transcription (JAK/STAT) path‐
way. Upon activator cytokine binding to its receptor on cell surface (e.g.,IL-6 receptor), JAK/STAT pathway is activat‐
ed (left) leading to sequential cell response. Inhibition signalling process by cucurbitacins is indicate on JAK or STAT
STAT signalling.
8. Conclusions
This review has highlighted the interest or importance of some phytochemicals present in
members of the Cucurbitaceae family, a group of plants used for a long time for many purposes
such as ornamental, food, and medicinal. It is in this last area where their phytochemicals
constituents have been pointed out as responsible for their medicinal properties. Flavonoids,
carotenoids, sterols, oils, vitamins, and minerals are some of these phytochemicals, but is the
terpenoid fraction known as cucurbitacins that has received special attention. This is because
such compound has been associated as a potential cytotoxic compounds. More than ten years
ago, a large number of cucurbitacins have been isolated and the use or applications for the
treatment of different types of cancer was described. The review also described details about
the mechanisms of how these phytochemicals act at the cellular level, but it seems that they
are not specifically bound protein targets forming thioethers bonds through a Michael-type
addition. This would allow these compounds to be conjugated with a broad array of potential
proteins targets, many of which would be inhibited or disrupted as a consequence. As a result,
their value as chemical biology probes is still limited and must be confirmed by independent
means. The different findings of the reports reviewed also indicated that the binding mode of
Phytochemicals - Isolation, Characterisation and Role in Human Health298
cucurbitacins to protein targets means that optimization for selectivity would be unlikely to
work, which would make it very difficult to reduce toxicities or improve the therapeutic
window for future clinical applications. However, alternative ways that their potential
therapeutic utility could be improved in the future is through targeted delivery to tumour cells,
for example, through antibody-conjugation or incorporation in nanoparticles.
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